Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Linch · SciRah

Researcher profile · Semantic Scholar

M. Linch

Share profile

M. Linch — researcher profile on SciRah

h-index: 30
Works: 132
Citations: 3,702

Most-cited papers

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
T. Powles, M. Kockx, A. Rodríguez-Vida, I. Durán +21 more
2019Nature Medicine534 citations Open access
Semantic Scholar
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
B. Szabados, M. Kockx, Z. Assaf, Pieter-Jan van Dam +26 more
2022European Urology186 citations Open access
Semantic Scholar
Molecular and histopathology directed therapy for advanced bladder cancer
C. Alifrangis, Ursula McGovern, A. Freeman, T. Powles +1 more
2019Nature reviews. Urology163 citations
Semantic Scholar
Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
B. Szabados, N. van Dijk, Yen Tang, M. S. van der Heijden +7 more
2018European Urology111 citations
Semantic Scholar
Control of MT1-MMP transport by atypical PKC during breast-cancer progression
C. Rossé, Catalina Lodillinsky, L. Fuhrmann, M. Nourieh +15 more
2014Proceedings of the National Academy of Sciences of the United States of America92 citations Open access
Semantic Scholar
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
T. Powles, A. Rodríguez-Vida, I. Durán, S. Crabb +16 more
201882 citations
Semantic Scholar
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Evan Y. Yu, M. Kolinsky, W. Berry, M. Retz +18 more
2022European Urology78 citations Open access
Semantic Scholar
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
K. Litchfield, S. Stanislaw, L. Spain, L. Gallegos +176 more
2020Cell Reports70 citations Open access
Semantic Scholar
aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization
E. Soriano, M. E. Ivanova, G. Fletcher, P. Riou +13 more
2016Developmental Cell69 citations Open access
Semantic Scholar
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
M. Linch, G. Goh, C. Hiley, Y. Shanmugabavan +30 more
2017Annals of Oncology60 citations Open access
Semantic Scholar
Equivocal, explicit and emergent actions of PKC isoforms in cancer
P. Parker, Sophie J L Brown, V. Calleja, P. Chakravarty +7 more
2020Nature Reviews. Cancer59 citations
Semantic Scholar
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Evan Y. Yu, C. Massard, M. Retz, A. Tafreshi +14 more
2019Journal of Clinical Oncology55 citations
Semantic Scholar
Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation
Morgan L. Jones, F. Beuron, Aaron J. Borg, A. Nans +7 more
2020Nature Communications50 citations Open access
Semantic Scholar
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Y. S. Wong, K. Joshi, P. Khetrapal, Mazlina Ismail +21 more
2018Journal of Experimental Medicine49 citations Open access
Semantic Scholar
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
A. Angelis, M. Linch, G. Montibeller, T. Molina-López +5 more
2019Social Science & Medicine (1967)38 citations Open access
Semantic Scholar
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
A. Choudhury, C. Higano, J. de Bono, N. Cook +22 more
2022Clinical Cancer Research36 citations Open access
Semantic Scholar
Evolving adoptive cellular therapies in urological malignancies.
Y. S. Wong, K. Joshi, M. Pule, K. Peggs +3 more
2017The Lancet Oncology32 citations Open access
Semantic Scholar
421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT
M. Linch, Z. Pápai, I. Takács, E. Imedio +7 more
2021Journal for ImmunoTherapy of Cancer30 citations Open access
Semantic Scholar
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
M. Linch, S. Gennatas, Stanislav Kazikin, J. Iqbal +8 more
2014BMC Cancer30 citations Open access
Semantic Scholar
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.
B. Szabados, A. Rodríguez-Vida, I. Durán, S. Crabb +15 more
2021European Urology Oncology28 citations Open access
Semantic Scholar
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
S. Hussain, J. Lester, R. Jackson, M. Gornall +16 more
2022The Lancet Oncology24 citations Open access
Semantic Scholar
Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective
Robert Jones, S. Crabb, M. Linch, A. Birtle +6 more
2024British Journal of Cancer21 citations Open access
Semantic Scholar
Immune checkpoint inhibitor induced large vessel vasculitis
Daisy Henderson, Gelareh Eslamian, D. Poon, S. Crabb +5 more
2020BMJ Case Reports19 citations Open access
Semantic Scholar
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
A. Kollár, Marco Maruzzo, C. Messiou, E. Cartwright +11 more
2014Clinical Sarcoma Research18 citations Open access
Semantic Scholar
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
F. Orlando, A. Romanel, B. Trujillo, M. Sigouros +15 more
2022NAR Cancer17 citations Open access
Semantic Scholar
Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
P. Fong, M. Retz, A. Drakaki, C. Massard +15 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
T. Powles, M. Kockx, A. Rodríguez-Vida, I. Durán +21 more
2023Nature Medicine15 citations Open access
Semantic Scholar
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma
Nadia Yousaf, S. Harris, J. Martin-Liberal, S. Stanway +8 more
2015Clinical Sarcoma Research15 citations Open access
Semantic Scholar
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
R. Aggarwal, Jing-Song Zhang, Xin-Hua Zhu, P. Monk +11 more
2023Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
T. Powles, Mark Kockx, A. Rodríguez-Vida, I. Durán +21 more
2020Nature Medicine13 citations Open access
Semantic Scholar
A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS).
D. Castellano, I. Durán, A. Rodríguez-Vida, S. Crabb +16 more
2018Annals of Oncology13 citations Open access
Semantic Scholar
Cardiovascular Complications of Prostate Cancer Therapy
Courtney M. Campbell, Kathleen W. Zhang, A. Collier, M. Linch +4 more
2020Current Treatment Options in Cardiovascular Medicine12 citations
Semantic Scholar
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study.
Gianmarco Leone, Y. N. S. Wong, Robert J. Jones, P. Sankey +24 more
2025Journal of Clinical Oncology11 citations Open access
Semantic Scholar
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
A. Hansen, G. Shapiro, K. Do, Rajiv Kumar +16 more
201711 citations
Semantic Scholar
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
A. M. Mahedi Hasan, P. Cremaschi, D. Wetterskog, A. Jayaram +19 more
2023Nature Communications10 citations Open access
Semantic Scholar
Targeting protein kinase C in sarcoma.
J. Martin-Liberal, A. Cameron, J. Claus, I. Judson +2 more
2014Biochimica et Biophysica Acta10 citations
Semantic Scholar
Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).
S. Hussain, J. Lester, R. Jackson, M. Gornall +13 more
20208 citations
Semantic Scholar
AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
J. de Bono, A. Hansen, Ananya Choudhury, N. Cook +15 more
2018Annals of Oncology7 citations Open access
Semantic Scholar
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
W. Cross, Iben Lyskjær, Christopher Davies, A. Bunkum +242 more
2025Genome Biology6 citations Open access
Semantic Scholar
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.
M. Linch, Gianmarco Leone, Y. S. Wong, Robert J. Jones +16 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
J. Waterhouse, J. Hull, M. Linch
2020European Urology6 citations Open access
Semantic Scholar
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
Y. S. Wong, P. Sankey, D. Josephs, Robert J. Jones +16 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
Evan Y. Yu, C. Massard, M. Retz, A. Tafreshi +14 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
C. Massard, M. Retz, P. Hammerer, F. Quevedo +15 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).
G. von Amsberg, U. Emmenegger, D. Robbrecht, Cagatay Arslan +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results
P. Monk, J. Zhang, D. Costin, D. Petrylak +8 more
2021Annals of Oncology5 citations Open access
Semantic Scholar
199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
B. Szabados, A. Rodríguez-Vida, I. Durán, S. Crabb +15 more
20205 citations Open access
Semantic Scholar
Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.
M. Morris, M. Linch, S. Crabb, T. Beer +8 more
2023Journal of Clinical Oncology4 citations
Semantic Scholar
BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).
R. Aggarwal, D. Costin, Jing-Song Zhang, L. Karsh +6 more
20214 citations
Semantic Scholar
Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
M. Linch, Y. S. Wong, Robert J. Jones, P. Sankey +25 more
2021Clinical research4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Crabb×16
Invite
S. Crabb — researcher profile on SciRah
T. Powles×13
Invite
T. Powles — researcher profile on SciRah
J. de Bono×9
Invite
J. de Bono — researcher profile on SciRah
A. Rodríguez-Vida×8
Invite
A. Rodríguez-Vida — researcher profile on SciRah

×8

Invite

I. Durán — researcher profile on SciRah

Invite

A. Pous — researcher profile on SciRah

U. A. Herranz×8

Invite

U. A. Herranz — researcher profile on SciRah

Invite

A. Ravaud — researcher profile on SciRah

Invite

D. Maillet — researcher profile on SciRah

Invite

C. Suárez — researcher profile on SciRah

Invite

K. Mousa — researcher profile on SciRah

Invite

B. Szabados — researcher profile on SciRah